Anna-Carin Olin with team PExA won the Arvid Carlsson Award 2020

2 oktober, 2020

This year’s Arvid Carlsson Award by Sahlgrenska Science Park was awarded to Anna-Carin Olin with team, PExA, for turning academic cross-functional research into a marketed solution that addresses the rising need for biomarker identification and early diagnosis of lung disease through non-invasive measurement of the small airways.

Diseases of the lung represents an area of significant unmet medical need and increasing global prevalence, where the emergence of personalised medicine can make a huge difference with the support of effective biomarker analysis.

“Anna-Carin Olin and her team show true entrepreneurship in offering both a product for immediate use in today’s research, as well as pioneering the implementation of new diagnostic standards enabling future use of novel treatment options,” says Marianne Dicander Alexandersson, chairman of Sahlgrenska Science Park and the award jury.

“It is really an honor to receive this award, it means a lot to me and everyone working with PExA”, says Anna-Carin Olin.

Last year’s winner, ProfessorJens Nielsen, CEO BioInnovation Institute, Copenhagen, passed the prize on at a ceremony yesterday at the life science event Park Annual.

2020 marked the 15th anniversary of the event with the theme Sector Convergence. All sessions from the day are published on parkannual.com.

Since 2017, Sahlgrenska Science Park pays tribute to innovation, knowledge and competence in conjunction with good entrepreneurship through this award in Nobel Prize winner Arvid Carlsson’s name.

Jury 2020
The board of directors Sahlgrenska Science Park:
Marianne Dicander Alexandersson, Chairman
Helena Holmberg, Member, The Region Västra Götaland
Göran Landberg, University of Gothenburg
Ann-Sofie Cans, Chalmers University of Technology
Hans Rothenberg, The City of Gothenburg
Kristian Vramsten, The City of Mölndal
Anders Hyltander (adj), Sahlgrenska University Hospital

Photo: Ceremony at Park Annual on 1 Oct 2020. From the left: Charlotta Gummeson, CEO, Sahlgrenska SP, Leif Johansson, Chairman of the board, AstraZeneca, Anna-Carin Olin, PExA, Marianne Dicander Alexandersson, Chairman of the Board, Sahlgrenska SP, Jens Nielsen, CEO, BII

About Anna-Carin Olin and PExA
Anna Carin Olin, researcher and inventor of PExA, is today the company’s research director. She has medical training and is a consultant and Professor of Occupational and Environmental medicine, directing research at the Sahlgrenska Academy’s Unit for Occupational and Environmental Medicine, AMM, at the University of Gothenburg. Anna-Carin has been involved in PExA’s business development since the 2000s.

PExA develops and commercializes a unique technology aimed for the discovery of early biomarkers in the field of respiratory medicine. More info about PExA.

About Arvid Carlsson
Arvid Carlsson, born 1923, was awarded the Nobel Prize in medicine for ”discoveries concerning signal transduction in the nervous system ” in 2000. Among other things, he studied the neurotransmitters dopamine and serotonin. He shared the award with the Americans Paul Greengard and Eric R. Kandel. Arvid Carlsson’s research led to the recognition that Parkinson’s disease is caused by dopamine deficiency in some parts of the brain and subsequently to the production of Levodopa, an effective drug against this disease. Arvid Carlsson was active until 2018 in his company A. Carlsson Research at Sahlgrenska Science Park in Gothenburg.

About Sahlgrenska Science Park
Sahlgrenska Science Park is an inclusive Open Arena for the new world of Life Science, focusing on innovation and business acceleration. Well-connected and with a non-profit approach, we provide the Life Science community with tailored advice and support to match and catalyse ideas. Bringing together the powers of industry, academia, healthcare and government, we offer an ecosystem for innovators and businesses to collaborate and grow within. Our vision is to establish West Sweden as a world class life science region by 2030, with sustainable and competitive companies on a global market.